Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Hye Rim Seo"'
Autor:
Hye-Rim Seo1,2, Ah-Rong Nam1, Ju-Hee Bang1, Kyoung-Seok Oh1, Jae-Min Kim1,2, Jeesun Yoon3, Tae-Yong Kim1,3, Do-Youn Oh1,2,3 ohdoyoun@snu.ac.kr
Publikováno v:
Cancer Research & Treatment. Apr2022, Vol. 54 Issue 2, p541-553. 13p.
Autor:
Kyoung Seok Oh, Hye Rim Seo, Jae-Min Kim, Ah Rong Nam, Tae Yong Kim, Ju Hee Bang, Mei Hua Jin, Do Youn Oh, Jeesun Yoon
Publikováno v:
Cancer Letters. 516:38-47
Olaparib, a potent PARP inhibitor, has been shown to have great anti-tumor effects in some tumor types. Although biliary tract cancer (BTC) is a good candidate for DNA damage response (DDR)-targeted agents, targeted DDR inhibitors, including olaparib
Autor:
Hye Rim Seo, Byung In Lim
Publikováno v:
Journal of Economics Studies. 39:141-160
Autor:
Kyoung Seok Oh, Tae Yong Kim, Ju Hee Bang, Mei Hua Jin, Jae Min Kim, Jeesun Yoon, Do Youn Oh, Ah Rong Nam, Hye Rim Seo
Publikováno v:
Gastric Cancer. 24:1003-1020
To date, many efforts have been made to understand the resistance mechanism of trastuzumab in human epidermal growth factor receptor 2 (HER2)-positive breast and gastric cancer. However, there is still a huge unmet medical need for patients with tras
Publikováno v:
Cancer Research and Treatment : Official Journal of Korean Cancer Association
PurposeCurrently, the DNA damage response (DDR) pathway represents a key target for new cancer drug development. Advanced biliary tract cancer (BTC) has a poor prognosis because of the lack of efficacious treatment options. Although DNA repair pathwa
Autor:
Kyoung-Seok Oh, Ah-Rong Nam, Ju-Hee Bang, Hye-Rim Seo, Jae-Min Kim, Jeesun Yoon, Tae-Yong Kim, Do-Youn Oh
Publikováno v:
Oncogene. 41(32)
Despite its clinical efficacy in HER2-positive cancers, resistance to trastuzumab inevitably occurs. The DNA damage response (DDR) pathway is essential for maintaining genomic stability and cell survival. However, the role of the DDR pathway in HER2-
Autor:
Jae-Min Kim, Ju-Hee Bang, Tae Yong Kim, Do-Youn Oh, Ah-Rong Nam, Jeesun Yoon, Hye-Rim Seo, Kyoung-Seok Oh
Publikováno v:
Cancer research and treatment. 54(2)
Purpose Up to 20% of patients with biliary tract cancer (BTC) have alterations in DNA damage response (DDR) genes, including homologous recombination (HR) genes. Therefore, the DDR pathway could be a promising target for new drug development in BTC.
Autor:
Mei-Hua, Jin, Ah-Rong, Nam, Ju-Hee, Bang, Kyoung-Seok, Oh, Hye-Rim, Seo, Jae-Min, Kim, Jeesun, Yoon, Tae-Yong, Kim, Do-Youn, Oh
Publikováno v:
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 24(5)
To date, many efforts have been made to understand the resistance mechanism of trastuzumab in human epidermal growth factor receptor 2 (HER2)-positive breast and gastric cancer. However, there is still a huge unmet medical need for patients with tras
Autor:
Do Youn Oh, Kyoung Seok Oh, Tae Yong Kim, Ah Rong Nam, Hye-Rim Seo, Woochan Park, Jae-Min Kim, Ju Hee Bang, Mei Hua Jin
Publikováno v:
Cancer Research and Treatment : Official Journal of Korean Cancer Association
Purpose The soluble form programmed death-ligand 1 (sPDL1) has immunosuppressive properties and is being studied as a candidate biomarker for immuno-oncology drug development. We measured the serum sPDL1 at pre-and post-chemotherapy and evaluated its
Autor:
Ah-Rong Nam, Jeesun Yoon, Ju-Hee Bang, Tae Yong Kim, Jae-Min Kim, Do-Youn Oh, Hye-Rim Seo, Kyoung-Seok Oh
Publikováno v:
Cancer Research. 81:1079-1079
Background: DNA damage response (DDR) pathway is essential for maintaining genomic stability, cell survival, and tumorigenesis. However, the roles of DDR pathway in HER2-positive tumors remain unclear. This study aims to discover the function of DDR